嘉事堂(002462) - 2024 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2024 was ¥12,838,830,705.91, a decrease of 13.70% compared to ¥14,877,717,780.55 in the same period last year[10]. - Net profit attributable to shareholders was ¥168,219,105.16, representing an increase of 8.19% from ¥155,489,204.07 in the previous year[10]. - The net profit after deducting non-recurring gains and losses was ¥106,772,183.30, down 28.38% from ¥149,081,767.85 in the same period last year[10]. - The net cash flow from operating activities was negative at ¥211,333,789.73, a decline of 124.83% compared to ¥851,290,876.21 in the previous year[10]. - Basic and diluted earnings per share were both ¥0.58, an increase of 9.43% from ¥0.53 in the previous year[10]. - Total assets at the end of the reporting period were ¥14,792,519,439.69, a decrease of 13.60% from ¥17,120,851,592.43 at the end of the previous year[10]. - Net assets attributable to shareholders increased by 2.18% to ¥4,332,900,587.97 from ¥4,240,525,334.01 at the end of the previous year[10]. Revenue Breakdown - The pharmaceutical wholesale segment accounted for 94.30% of total revenue, generating CNY 12.11 billion, down 13.61% year-on-year[18]. - The medical logistics segment saw a revenue increase of 16.87%, reaching CNY 225.57 million, compared to CNY 193 million in the previous year[18]. - The company's operating costs decreased by 12.95% to CNY 12.06 billion, reflecting the reduction in revenue[17]. Cash Flow and Investments - The cash flow from operating activities showed a significant decline of 124.83%, resulting in a net cash flow of -CNY 211 million[17]. - Investment income for the reporting period amounted to CNY 427,534.50, contributing 0.11% to total profit[20]. - The company recorded a significant increase in investment amounting to CNY 45,529,012.27, a 551.40% increase compared to the same period last year[28]. Subsidiary Performance - The subsidiary Anhui Jiashitong Medical Technology Co., Ltd. reported a net profit of CNY 6,613,364.92, contributing over 10% to the company's net profit[33]. - Shenzhen Jiashitong Kangyuan Medical Equipment Co., Ltd. experienced a net loss of CNY 26,645,229.42, indicating challenges in its operations[33]. - The subsidiary Sichuan Jiashitong Xinxin Medical Equipment Co., Ltd. achieved a revenue of CNY 590,526,103.01 and a net profit of CNY 7,245,380.51 during the reporting period[34]. Shareholder and Dividend Policy - The company plans not to distribute cash dividends or issue bonus shares[1]. - The total number of shares outstanding is 291,707,120, with 99.93% being unrestricted shares[56]. - The company reported no major impacts from related party debts on its operational results and financial status[48]. Accounts Receivable and Bad Debt - Accounts receivable stood at CNY 7,708,056,924.11, making up 52.11% of total assets, an increase of 2.92%[23]. - The company recorded a bad debt provision of ¥69,606,485.2 during the period, increasing the total bad debt provision to ¥355,114,642.17, which is a rise of approximately 22.6% from the previous period[179]. - The company has written off accounts receivable totaling ¥71,870,103.01 during the period, with the write-off procedures duly followed[181]. Financial Management and Strategy - The company plans to actively respond to the impact of drug and medical supplies procurement policies by optimizing its business and product structure[35]. - The company is focusing on expanding new product introductions and enhancing terminal sales to mitigate the impact of price reductions in drugs and supplies[35]. - The company plans to focus on improving cash flow management and exploring new investment opportunities to enhance financial stability in the future[85]. Accounting Policies and Financial Reporting - The financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance[97]. - The company recognizes goodwill when the acquisition cost exceeds the fair value of identifiable net assets acquired[107]. - The company assesses the fair value of financial assets and liabilities at each balance sheet date, ensuring compliance with the fair value measurement hierarchy[142]. Legal and Compliance - There were no significant legal disputes or administrative penalties reported during the period[41]. - The company has not faced any non-operating fund occupation by controlling shareholders or related parties during the reporting period[41].